Review
Chemistry, Medicinal
Zhen-Xi Niu, Ya-Tao Wang, Nan Lu, Jin-Feng Sun, Peng Nie, Piet Herdewijn
Summary: Lung cancer remains a significant contributor to global cancer-related mortality with a large population of non-small cell lung cancer (NSCLC) patients facing incurable conditions. Chemoradiation is a fundamental component in the management of locally advanced NSCLC amenable to surgical resection. Progress has been made in understanding the disease biology and tumor progression mechanisms, as well as advancements in early detection and multimodal therapeutic interventions. However, curative interventions and survival outcomes for NSCLC remain discouragingly low, especially in the context of metastatic disease. Continued research on novel pharmaceutical agents and combination therapies is crucial to broaden the scope of clinical advantages and improve outcomes for NSCLC.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Medicine, General & Internal
Isa Mambetsariev, Leonidas Arvanitis, Jeremy Fricke, Rebecca Pharaon, Angel R. Baroz, Michelle Afkhami, Marianna Koczywas, Erminia Massarelli, Ravi Salgia
Summary: EGFR-mutated lung adenocarcinoma patients can transform into SCLC after receiving TKI therapy. This study evaluated 9 patients who underwent such transformation and found that they had unique clinical, molecular, and histological characteristics at different time points. The findings are important for understanding the molecular heterogeneity and clinical outcomes of this EGFR TKI resistance subtype.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Hongfang Zhang, Hong Jiang, Lucheng Zhu, Jiawei Li, Shenglin Ma
Summary: This review summarizes the recent progress in understanding the impact of CAFs on NSCLC over the past five years, discussing how CAFs interact with cancer cells and their effects on tumor growth, metastasis, and immune escape. The review highlights the implications for anti-NSCLC therapies, emphasizing the importance of a deeper understanding of the molecular biology of CAFs for the development of novel treatments.
Review
Oncology
Lin Zhang, Weihao Lin, Fengwei Tan, Ning Li, Qi Xue, Shugeng Gao, Yibo Gao, Jie He
Summary: This study provides an overview of the clinical trials on Sintilimab for non-small cell lung cancer (NSCLC) conducted in China, showing its effectiveness and tolerability, but further research is needed.
BIOMARKER RESEARCH
(2022)
Article
Biochemistry & Molecular Biology
Meina Wang, Roy S. Herbst, Chris Boshoff
Summary: Over the past two decades, molecular targeted therapies and immunotherapies have significantly improved outcomes for non-small-cell lung cancer (NSCLC), but the majority of advanced NSCLCs eventually become resistant. The future challenge lies in the application of predictive biomarkers for patient stratification in order to better manage NSCLC.
Review
Oncology
Reem Altaf, Sarmad Sheraz Jadoon, Syed Aun Muhammad, Umair Ilyas, Yongtao Duan
Summary: Lung cancer, responsible for thousands of cancer-related deaths, has long been a challenging disease to treat. However, advancements in understanding the molecular pathways and biology of lung cancer have changed its management. Immunotherapies, which previously failed, are now emerging as a novel and effective therapy for lung cancer. This review article focuses on immune checkpoint inhibitors, specifically CTLA-4 and PDL-1 inhibitors, and critically analyzes studies and clinical trials to determine their potential benefits, risks, and adverse events in treating lung carcinoma.
FRONTIERS IN ONCOLOGY
(2022)
Review
Medicine, General & Internal
Meagan Miller, Nasser Hanna
Summary: Lung cancer remains a leading cause of cancer-related mortality worldwide, with non-small cell lung cancer being incurable for most patients. The optimal treatment for locally advanced NSCLC includes chemoradiation, while immunotherapy can be added for unresectable cases post-chemoradiation. Advances in targeted therapies and immunotherapy have transformed the landscape of NSCLC treatment.
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Review
Oncology
Jing Han, Yang Liu, Sen Yang, Xuan Wu, Hongle Li, Qiming Wang
Summary: BRAF and KRAS mutations play a significant role in NSCLC by activating the RAS/RAF/MEK/ERK signaling pathway. Current approved therapies include BRAF and MEK inhibitors, while combination with other drugs may enhance therapeutic effects. Further research is needed to explore optimal drug combinations for treating lung cancer patients.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Review
Oncology
Mahmood Araghi, Reza Mannani, Ali Heidarnejad Maleki, Adel Hamidi, Samaneh Rostami, Salar Hozhabri Safa, Fatemeh Faramarzi, Sahar Khorasani, Mina Alimohammadi, Safa Tahmasebi, Reza Akhavan-Sigari
Summary: Lung cancer is the leading cause of cancer-related death globally, and significant advancements have been made in the last decade in diagnosing and treating NSCLC through molecular translational research. Targeted therapy, specifically aimed at specific genes, proteins, or the tumor microenvironment, has shown the most successful outcomes in NSCLC treatment. Efforts are currently focused on improving targeted therapy to enhance cancer treatment outcomes and patient quality of life. This updated study provides a comprehensive discussion on tumor target antigens and targeted therapy-related agents, along with a summary of available clinical trial studies for NSCLC patients.
CANCER CELL INTERNATIONAL
(2023)
Review
Pharmacology & Pharmacy
Quancheng Yang, Xuejia Zhai, Yi Lv
Summary: In recent decades, triptolide, a natural product derived from Tripterygium wilfordii, has shown promising therapeutic potential in immune inflammation and cancer treatment. This study analyzed a large number of manuscripts published between 2011 and 2021 to identify the research frontier and development trend of triptolide. The findings suggest that triptolide effectively inhibits the development and metastasis of non-small cell lung cancer (NSCLC) through various signaling pathways and molecular mechanisms. Furthermore, this article also discusses the potential of triptolide in tumor immunotherapy.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Immunology
Danming He, Lu Wang, Jiachen Xu, Jie Zhao, Hua Bai, Jie Wang
Summary: Immunotherapy has transformed the treatment of non-small cell lung cancer (NSCLC), particularly with the use of anti-PD-1/PD-L1 antibodies. However, the majority of NSCLC patients do not respond to these immune checkpoint inhibitors. Vascular abnormalities in tumors allow them to evade the immune system. Therefore, combining anti-angiogenic therapies with anti-PD-1/PD-L1 antibodies may enhance treatment effectiveness. This paper illustrates the mechanisms and summarizes clinical studies and predictive immunotherapeutic biomarkers to provide more treatment options for NSCLC patients.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Angelica D'Aiello, Emily Miao, Haiying Cheng
Summary: Central nervous system (CNS) metastases are common among patients with non-small cell lung cancer (NSCLC). Recent advances in local and systemic therapies have greatly improved outcomes for NSCLC patients with CNS involvement. Ongoing efforts are necessary to optimize CNS metastases management and develop new therapeutics.
Letter
Medicine, General & Internal
Hollis Viray, Deepa Rangachari, Daniel B. Costa
Summary: The study reported initial data of trastuzumab deruxtecan in the treatment of lung cancers with ERBB2 mutations, including patients who had previously received ineffective ERBB2 tyrosine kinase inhibitors.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Jia Li Low, Yiqing Huang, Kenneth Sooi, Yvonne Ang, Zhi Yao Chan, Katie Spencer, Anand Devaprasath Jeyasekharan, Raghav Sundar, Boon Cher Goh, Ross Soo, Wei Peng Yong
Summary: The study found that there was no significant difference in survival outcomes, toxicity, and costs between 100 mg and 200 mg doses of pembrolizumab in the treatment of advanced non-small cell lung cancer. The lower dose of 100 mg showed potential cost savings without compromising efficacy, suggesting the need for further investigation through a randomized trial.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Review
Pharmacology & Pharmacy
Hang Yan, Shengjie Tang, Shoujun Tang, Jun Zhang, Haiyang Guo, Chao Qin, Haiyang Hu, Chuan Zhong, Li Yang, Yunhe Zhu, Haining Zhou
Summary: Non-small cell lung cancer (NSCLC) is a common malignant tumor with suboptimal clinical success due to late diagnosis, limited treatment options, high recurrence rates, and drug resistance. MicroRNAs (miRNAs), small non-coding RNAs, have emerged as important players in NSCLC initiation, progression, and drug resistance. This review provides an overview of miRNA dysregulation and resistance in NSCLC and discusses their potential applications in different anti-cancer treatments.
FRONTIERS IN PHARMACOLOGY
(2022)
